HCPLive Network

Leading National Oncology Publisher Starts New Business Unit with New York Office

Leading National Oncology Publisher Starts New Business Unit With New York Office
New MJH & Associates unit will focus on targeted therapies for cancer and other diseases
PLAINSBORO, NJ – August 24, 2012 – The rapidly growing, new type of drug treatments known as targeted therapies has inspired a spin-off at a leading national healthcare publisher. Plainsboro-based MJH & Associates, which also owns Intellisphere, LLC, publisher of titles such as Oncology Live, Oncology & Biotechnology News, Oncology Nursing News, Urology in Cancer Care and Onclive.com, is expanding and introducing a New York operation.
The new entity, “Targeted Healthcare Communications,” will be based in Westchester, NY. This New York-area business unit will immediately assume publication of existing titles International Journal for Targeted Therapies, Targeted Therapy News, Oncology Fellows and Horizons. Additionally, the New York team will begin developing other specialized, targeted therapy publications and expanding its digital offering.
“This dedicated model gives our targeted therapies team the flexibility needed to quickly respond to emerging science and to service the unique information needs of this audience,” said Tighe Blazier, COO of MJH & Associates.
The company has appointed Peter Ciszewski president and managing director of Targeted Healthcare Communications’ New York office. Ciszewski was formerly president of the Intellisphere Oncology team in Plainsboro. Lisa Greene, vice president of sales and marketing, and Scott Harwood, director of sales, will also join the New York team.
Jack Lepping, formerly an executive vice president, has been appointed president of the Intellisphere Oncology Specialty Group in Plainsboro, with an emphasis on new publications and product development. The other titles published by Intellisphere will be unchanged, and Oncology Live remains the official journal of Physicians’ Education Resource (PER), a leading provider of continuing medical education for oncology physicians and technicians.
For more information about Targeted Healthcare Communications’ publications, click here.
About Michael J. Hennessy & Associates, Inc.
MJH & Associates is a healthcare publishing company that reaches nearly every sector of healthcare professionals, providing resources and information to physicians, pharmacists, managed care professionals, and many others. MJH & Associates combines the power of an established network of publications and websites with the customer service focus and customization capabilities of a boutique firm.
Mike Gross
For MJH & Associates
267-932-8760 x 310
856-628-6169 (mobile)

Further Reading
The US Food and Drug Administration today approved Merck’s Gardasil 9, a vaccine that offers protection against 5 more types of Human Papillomavirus (HPV) than original Gardasil. In addition to preventing cervical, vulvar, vaginal and anal cancers caused by HPV types 16 and 18 (those prevented by the older version of Gardasil) Gardasil 9 also prevents those cancers caused by HPV strains 31, 33, 45, 52, and 58.
Obizur (Antihemophilic Factor [Recombinant], Porcine Sequence) has been approved to treat acquired hemophilia A (acquired Factor VIII deficiency), a rare, non-inherited form of hemophilia.
The US Food and Drug Administration (FDA) has approved the use of an experimental drug to treat patients who have Ebola Virus Disease.
More Reading